120 results
8-K
EX-99.1
STRO
Sutro Biopharma Inc
13 May 24
Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
4:30pm
and development of precisely designed cancer therapeutics, to transform what science can do for patients. Sutro’s fit-for-purpose technology, including
8-K
EX-5.1
STRO
Sutro Biopharma Inc
2 Apr 24
Entry into a Material Definitive Agreement
5:10pm
to the Registration Statement and is not to be relied upon for any other purpose. In providing this letter, we are opining only as to the specific
8-K
EX-1.1
STRO
Sutro Biopharma Inc
2 Apr 24
Entry into a Material Definitive Agreement
5:10pm
-effective amendment thereto or the Rule 462(b)
Registration Statement, if any, has been issued and no proceeding for that purpose or pursuant to Section 8A … of the Stock has been issued by the Commission, and no proceeding for that purpose or pursuant to Section 8A of the Securities Act has been
424B5
0s9vy4wyu4la2u6
2 Apr 24
Prospectus supplement for primary offering
4:58pm
8-K
EX-99.1
ieyzebwzf7spf96
2 Apr 24
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
6:04am
8-K
EX-99.1
ofux0t 2b
25 Mar 24
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones
4:30pm
S-8
z6hw2e esfusd
27 Feb 24
Registration of securities for employees
4:33pm
S-8
er7mwsxe l9n
27 Feb 24
Registration of securities for employees
4:33pm
S-8
EX-5.1
2y0dlfw w5u85j6z435
27 Feb 24
Registration of securities for employees
4:33pm
8-K
EX-1.1
b8ry31qpxol87o
9 Feb 24
Other Events
4:27pm
8-K
EX-5.1
a94k0vl1or9
9 Feb 24
Other Events
4:27pm
424B5
n6taf
9 Feb 24
Prospectus supplement for primary offering
4:25pm
8-K
EX-99.1
ph2553nv
8 Jan 24
Results of Operations and Financial Condition
7:31am